Please login to the form below
lenvatinib
This page shows the latest lenvatinib news and features for those working in and with pharma, biotech and healthcare.
Roche’s Tecentriq/Avastin combo improves survival in liver cancer
Merck is testing Keytruda alongside partner Eisai’s kinase inhibitor Lenvima (lenvatinib) – already-approved for first-line HCC – in the Leap-002 trial, picking up a breakthrough designation from the FDA
Latest news
-
Merck CFO: we’re not only about Keytruda
He said the performance of other cancer drugs like Lenvima (lenvatinib) and Lynparza (olaparib), revenue from which doubled in the quarter – as well as the vaccine portfolio headed by cervical cancer
-
Merck says it has plenty in the pipe beyond Keytruda
AstraZeneca-partnered Lynparza (olaparib) and Eisai-partnered Lenvima (lenvatinib) that the company is also expecting to show significant growth in the coming years.
-
Analysts look beyond Keytruda in Merck’s future
Human papillomavirus (HPV) vaccine Gardasil was up a third to $835m, and there were good performances for cancer drugs Lynparza (olaparib) and Lenvima (lenvatinib), partnered with AstraZeneca and Eisai, respectively.
-
Pfizer’s plans for Inlyta go awry with failed adjuvant trial
nivolumab) and Exelixis’ multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
-
$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima
rights for Lenvima (lenvatinib) and start a series of clinical trials in combination with Keytruda (pembrolizumab).
More from news
Approximately 2 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Eisai: Bucking the trend with R&D growth
The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- New study identifies drugs that are safe to use in COVID-19 treatment
- Keytruda doubles five-year survival rate in NSCLC
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
